Navigation Links
Researchers issue state-of-the-state on genetic-based testing and treatment for breast cancer
Date:3/25/2014

(Lebanon, NH, 03/24/2014)- Dartmouth researchers at its Norris Cotton Cancer Center have compiled a review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer. The paper entitled "Personalized Therapy for Breast Cancer" was accepted on March 17, 2014, for publication in Clinical Genetics. The paper discusses targeted therapies, new biomarkers, and the quality of commercially available testing methods.

Genomic testing is changing the way breast cancer is diagnosed and treated. By examining a woman's genes to look for specific mutations or biomarkers, treatment can be personalized to the tumor cell's biology and a woman's genetics.

"A personalized approach increases the precision and success of breast cancer treatment," said Gregory Tsongalis, PhD, director of Molecular Pathology at Norris Cotton Cancer Center and lead author of the paper. "Molecular profiling exposes a tumor's Achilles' heel. We can see what messages the tumor cells are receiving and sending. It is a biological intelligence gathering mission in an attempt to interrupt the disease.

According to Tsongalis large scale genetic testing of breast cancer is not yet part of routine clinical care as it is with lung and colon cancers, even though he and his team run a genetics laboratory for routine cancer care. Genetic testing according to Tsongalis is a powerful weapon in the diagnosis and treatment of breast cancer.

With results from the genetic testing of a tumor cell's biology, clinicians categorize breast cancer in ways that allow them to select the most effective treatments. Based on genetic biomarkers, there are three categories of breast cancer:

  • ER-positive breast cancer needs hormones, such as estrogen to grow. Estrogen fuels cancer cell growth, stops cancer cells from dying, and helps the cells lay down roots to maintain blood supply for tumors. ER-positive cancers are less aggressive and often treated with drugs that are selective estrogen receptor modulators (SERM), such as Tamoxifen, Raloxifene, Toremifene and aromatese inhibitors (AIs) such as Letrozole, Anastrozole and Exemestane. SERM drugs block estrogen from telling cancer cells to divide and grow; they have been shown successful in treating as well as preventing ER positive breast cancer. AIs block intake of estrogen in the system and reduce estrogen levels in serum, tissue, and tumor cells. AIs are commonly used in post-menopausal women.

  • HER2 positive breast cancer cells contain large amounts of protein that help them grow and multiply. Medications turn off the production of protein to stop tumor growth and kill cancer cells. HER2 treatments include Trastuzumab, Laptinib, Pertuzumab, and Trastuzumab Emtansine.

  • Triple negative (ER-negative/PR-negative/HER2-negative) breast cancer is the most aggressive type and has the poorest clinical outcome. There is no approved personalized therapy for triple negative, but research has identified six subtypes of tumors. This is the first step in identifying biomarkers that can lead to the development of personalized treatments.

"Genomic testing of breast cancer has expanded our understanding of the disease process and has proven more effective than traditional laboratory tests," said Tsongalis. "At NCCC all of our breast cancer patients are tested for abnormal copies of the HER2 gene using specially designed DNA probes."New biomarkers and the reclassification of cancers based on these biomarkers has led to the development of new, effective treatments that can be personalized to an individual breast cancer patient."


'/>"/>
Contact: Donna Dubuc
donna.M.Dubuc@Dartmouth.edu
603-653-3615
The Geisel School of Medicine at Dartmouth
Source:Eurekalert

Related medicine news :

1. Researchers identify impaired new learning in persons with Parkinsons disease
2. Researchers identify potential new therapeutic target for controlling high blood sugar
3. Ottawa researchers find new pathway connected to type 2 diabetes
4. Shoulder revision repair surgery not as successful 2 years later, say researchers
5. Researchers find significant increase in painkillers prescribed to US adults in the ER
6. Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment
7. Researchers destroy cancer with cryoablation & nanoparticle-encapsulated anticancer drug
8. NYU researchers find majority of Latinas are unaware of their risk of diabetes
9. UF researchers find drug therapy that could eventually reverse memory decline in seniors
10. Researchers identify carbohydrates in a coal mine for cancer detection
11. Researchers X-ray living cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... PA and London UK (PRWEB) , ... March ... ... the speed, agility and ability to gain site attention and engagement over the ... DrugDev educational webinar will discuss how partnering with the right ...
(Date:3/27/2017)... ... March 27, 2017 , ... A study by the founder of ... colleague, Sudeep Roy, MD, was recently published in the American Journal of Cosmetic ... details Drs. Buckingham and Roy’s study on the use of Electro Lube during the ...
(Date:3/27/2017)... Arizona (PRWEB) , ... March 27, 2017 , ... Buzzies ... the top 10 for Rent the Runway Foundation and UBS’ Project Entrepreneur. Mayo will ... York on April 8. , Project Entrepreneur’s second annual venture competition ignites bold ...
(Date:3/27/2017)... IL (PRWEB) , ... March 27, 2017 , ... ... systems, recently received the CE Certificate of Conformity for the Smart System® 20/20. ... or exceed the highest industry standards and specifications such as ANSI, ISO and ...
(Date:3/27/2017)... ... March 27, 2017 , ... American ... conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, a ... with the April edition of American Veterinarian™. , “We look forward ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017  Sanderling Ventures, portfolio company, Torax ... division of Johnson & Johnson. Torax manufactures and markets ... of gastro-esophageal reflux disease (GERD). The LINK device ... and the procedure is currently available in the ... Medical was founded by Sanderling Ventures, Mayo Medical ...
(Date:3/27/2017)... March 27, 2017 BioLineRx Ltd. (NASDAQ/TASE: ... announced today that AGI-134, an immunotherapy for the treatment of ... Ltd., will be featured at the upcoming American Association ... Washington, DC to be held on April 1-5, ... ...
(Date:3/27/2017)... FRANCISCO , March 27, 2017 ... expected to reach USD 16.0 billion by 2025, according ... The growing prevalence of chronic diseases is anticipated to ... chemistry analyzers, which thereby widens the scope for growth ... geriatric and bariatric population, which is highly susceptible to ...
Breaking Medicine Technology: